EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

Immune Response and Risk of Decompensation following SARS-CoV-2 Infection in Outpatients with Advanced Chronic Liver Disease

Anna Brujats, Anna Huerta, Rubén Osuna-Gómez iD, Albert Guinart-Cuadra iD, Andreu Ferrero-Gregori iD, Clàudia Pujol, German Soriano iD, Maria Poca iD, Javier Fajardo, Angels Escorsell iD, Adolfo Gallego, Silvia Vidal iD und 2 weitere

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms25158302 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Anna Brujats und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Insitute Sant Pau (IIB Sant Pau), 08041 Barc…. Hauptthemen laut MEDLINE: COVID-19, Immunoglobulin G, Liver Diseases, Outpatients. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Instituto de Salud Carlos III, ISCIII and Fondos Feder.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Advanced chronic liver disease (ACLD) is associated with a wide spectrum of immune dysfunction. The clinical impact of SARS-CoV-2 on the development of decompensation and immune response in unvaccinated outpatients has not as yet been clearly defined. This study aimed to evaluate the clinical and immunological impact of SARS-CoV-2 on outpatients with ACLD. This is an observational case–control study, in which ACLD outpatients were included prospectively and consecutively and classified into two groups: SARS-CoV-2 infected and non-infected. Patients’ baseline characteristics and infection data were collected and analyzed. Immunoglobulin G (IgG) levels against Spike 1 were evaluated. The primary endpoint was risk of liver decompensation during follow-up, assessed after propensity score matching and adjusted by Cox regression. Between October 2020 and July 2021, ACLD outpatients (n = 580) were identified, and 174 patients with clinical follow-up were included. SARS-CoV-2 infection incidence was 7.6% (n = 44). Risk of liver decompensation was significantly higher after infection (HR = 2.43 [1.01–5.86], p = 0.048) vs. non-infection. The time of IgG evaluation was similar in all patients (n = 74); IgG concentrations were significantly higher in compensated vs. decompensated patients (1.02 ± 0.35 pg/mL vs. 0.34 ± 0.16 pg/mL, p < 0.0001) and correlated with hemoglobin levels. The dysregulation of the innate immune response in patients with decompensated liver disease increased the risk of further decompensation following SARS-CoV-2, mainly due to a worsening of ascites.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Immunoglobulin GLiver DiseasesOutpatientsAgedFemaleHumansMaleMiddle AgedCase-Control StudiesChronic DiseaseProspective StudiesRisk Factors

Stichwörter der Autor:innen

SARS-CoV-2 infectionadvanced chronic liver disease (ACLD)anti-Spike 1 immunoglobulin Gdecompensationimmune response

Substanzen

Immunoglobulin G

Autor:innen und Institutionen

  • Department of Gastroenterology and Hepatology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Insitute Sant Pau (IIB Sant Pau), 08041 Barcelona, Spain.
  • Departament Medicina UAB, Universitat Autònoma de Barcelona, 08193 Barcelona, Spain.
  • Inflammatory Diseases Department, Institut Recerca Hospital de la Santa Creu i Sant Pau (IR Sant Pau), 08041 Barcelona, Spain.
  • Centre for Biomedical Research in Liver and Digestive Diseases Network (CIBERehd), Instituto de Salud Carlos III, 28029 Madrid, Spain.

ORCID-Profile: Rubén Osuna-Gómez, Albert Guinart-Cuadra, Andreu Ferrero-Gregori, German Soriano, Maria Poca, Angels Escorsell, Silvia Vidal, Edilmar Alvarado-Tapias

Förderung

  • Instituto de Salud Carlos III
  • ISCIII and Fondos Feder

Zitieren

APA

Brujats, A., Huerta, A., Osuna-Gómez, R., Guinart-Cuadra, A., Ferrero-Gregori, A., Pujol, C., Soriano, G., Poca, M., Fajardo, J., Escorsell, A., Gallego, A., Vidal, S., Villanueva, C., & Alvarado-Tapias, E. (2024). Immune Response and Risk of Decompensation following SARS-CoV-2 Infection in Outpatients with Advanced Chronic Liver Disease. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25158302

Vancouver

Brujats A, Huerta A, Osuna-Gómez R, Guinart-Cuadra A, Ferrero-Gregori A, Pujol C, et al. Immune Response and Risk of Decompensation following SARS-CoV-2 Infection in Outpatients with Advanced Chronic Liver Disease. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25158302

BibTeX
@article{Brujats2024,
  author = {Brujats, Anna and Huerta, Anna and Osuna-Gómez, Rubén and Guinart-Cuadra, Albert and Ferrero-Gregori, Andreu and Pujol, Clàudia and Soriano, German and Poca, Maria and Fajardo, Javier and Escorsell, Angels and Gallego, Adolfo and Vidal, Silvia and Villanueva, Càndid and Alvarado-Tapias, Edilmar},
  title = {Immune Response and Risk of Decompensation following SARS-CoV-2 Infection in Outpatients with Advanced Chronic Liver Disease},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms25158302}
}
Kostenlos starten →